What does this research mean for the field?

Circulating cell-free miR-25-3p is upregulated in the plasma of prostate cancer patients, correlates with higher tumor grade, and functionally promotes tumor aggressiveness by increasing cell proliferation, migration, and invasion. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the association between circulating cell-free microRNA levels and prostate cancer risk and aggressiveness using patient plasma and in vitro cell models.

September 2, 2026Non-Coding RNAOpen Access

Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness

View Full Paper

Ask AI

Bookmark

Authors

MNMonyse de Nóbrega HKHellen Kuasne MSMarilesia Ferreira de Souza

Discussion

Member takes

Overview

Case-control study reveals elevated plasma miR-25-3p in prostate cancer, indicating its potential as a non-invasive prognostic biomarker.

Key Points

To assess the association between circulating cell-free microRNA levels and prostate cancer risk and aggressiveness using patient plasma and in vitro cell models.
Screened prostate cancer candidate microRNAs from The Cancer Genome Atlas (miR-25-3p, miR-92a-1-5p, miR-92a-2-5p, and miR-148a-3p) and validated plasma levels via RT-qPCR in 80 prostate cancer patients and 40 controls from Brazil.
Evaluated clinicopathological correlations with microRNA expression across different disease grades.
Conducted functional in vitro assays using transient transfection of miR-25-3p in the LNCaP cell line to measure proliferation, colony formation, migration, invasion, and target gene expression.
Circulating cell-free miR-25-3p was significantly elevated in prostate cancer patients compared to controls (p = 0.013), while other candidate microRNAs showed no significant difference.
Patients with higher-grade disease (ISUP grade ≥2) exhibited significantly higher plasma levels of miR-25-3p compared to those with ISUP grade 1 (p = 0.020).
Overexpression of miR-25-3p promoted LNCaP cell proliferation, colony formation, migration, and invasion, and modulated the expression of BCL2L11, CDH1, CDKN1C, EZH2, and TP53.

Cite This Study

Nóbrega et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2f6c562ede874ec7735 https://doi.org/10.3390/ncrna12050033

View Full Paper

Ask AI

Bookmark

September 2, 2026Non-Coding RNAOpen Access

Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness

View Full Paper

Ask AI

Bookmark

Authors

MNMonyse de Nóbrega HKHellen Kuasne MSMarilesia Ferreira de Souza

Discussion

Member takes

Overview

Case-control study reveals elevated plasma miR-25-3p in prostate cancer, indicating its potential as a non-invasive prognostic biomarker.

Key Points

To assess the association between circulating cell-free microRNA levels and prostate cancer risk and aggressiveness using patient plasma and in vitro cell models.
Screened prostate cancer candidate microRNAs from The Cancer Genome Atlas (miR-25-3p, miR-92a-1-5p, miR-92a-2-5p, and miR-148a-3p) and validated plasma levels via RT-qPCR in 80 prostate cancer patients and 40 controls from Brazil.
Evaluated clinicopathological correlations with microRNA expression across different disease grades.
Conducted functional in vitro assays using transient transfection of miR-25-3p in the LNCaP cell line to measure proliferation, colony formation, migration, invasion, and target gene expression.
Circulating cell-free miR-25-3p was significantly elevated in prostate cancer patients compared to controls (p = 0.013), while other candidate microRNAs showed no significant difference.
Patients with higher-grade disease (ISUP grade ≥2) exhibited significantly higher plasma levels of miR-25-3p compared to those with ISUP grade 1 (p = 0.020).
Overexpression of miR-25-3p promoted LNCaP cell proliferation, colony formation, migration, and invasion, and modulated the expression of BCL2L11, CDH1, CDKN1C, EZH2, and TP53.

Cite This Study

Nóbrega et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2f6c562ede874ec7735 https://doi.org/10.3390/ncrna12050033

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark